Sign up for news updates

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

2018

Add ILCN as a preferred source
  • The IASLC Fight Against Lung Cancer in Peru and Latin America

    The IASLC Fight Against Lung Cancer in Peru and Latin America

    Uncategorized

    By Dr. Luis E. Raez, MD Posted: October 2018 Peru is one of the largest Latin American countries, with a population of approximately 28 million people. Cancer is not yet a leading cause of mortality because of the young median age of the population and other factors like the high prevalence of infectious diseases; in…

  • KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

    KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

    Systemic, Targeted, & Immune Therapies

    By Kara Nyberg, PhD Posted: August 2018 The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint in recent years. Among immunotherapy options, pembrolizumab emerged as an early frontrunner, along with nivolumab and atezolizumab, in the second-line treatment setting. Pembrolizumab now appears to be surging ahead…

  • Circulating Tumor Cell–Derived Patient eXplants: A New Tool for SCLC Research

    Circulating Tumor Cell–Derived Patient eXplants: A New Tool for SCLC Research

    Evolving Standards of Care

    By Caroline Dive, CBE, PhD, FMedSci, and Kris Frese, PhD Posted: August 2018 Small cell lung cancer (SCLC) is aggressive, disseminates early, and has a dismal prognosis.1 Its genomic landscape which reveals little in the way of obvious druggable targets, presents a significant challenge. One obstacle to a more comprehensive understanding of the biology and…

  • NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

    NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

    Regulatory Agency Perspective

    Posted: August 2018 In October 2017, the United States National Cancer Institute (NCI) launched a major effort to expand the discovery and validation of predictive biomarkers on cancer immunotherapy. This $56.3-million NCI initiative is part of the U.S. Cancer Moonshot, launched by former President Barack Obama and Vice President Joe Biden and funded by the…

  • The Budget Landscape with Dr. Douglas R. Lowy

    The Budget Landscape with Dr. Douglas R. Lowy

    Regulatory Agency Perspective

    By Erik MacLaren, PhD Posted: August 2018 The National Cancer Institute (NCI) and researchers who rely on the funding it provides have spent much of the past year under the shadow of expected cuts in federal funding. President Trump’s budget request last year proposed cutting the National Institutes of Health (NIH) budget overall by $7.7…

  • The IASLC Issues Liquid Biopsy Statement to Aid Understanding of Rapid Innovation

    The IASLC Issues Liquid Biopsy Statement to Aid Understanding of Rapid Innovation

    Evolving Standards of Care

    By Joy Curzio Posted: August 2018 Liquid biopsy is a powerful tool that can determine a patient’s molecular tumor profile and aid diagnosis, as well as therapeutic choices. Liquid biopsy can be applied as an alternative to tissue testing in cases where tumor testing is not possible or tissue is not adequate for multiple cancer…

  • Global Insights on New Clinical Practice Guideline for the Treatment of Malignant Pleural Mesothelioma

    Global Insights on New Clinical Practice Guideline for the Treatment of Malignant Pleural Mesothelioma

    Evolving Standards of Care

    By Hedy L. Kindler, MD Posted: August 2018 The American Society of Clinical Oncology (ASCO) has issued its first-ever clinical practice guidelines on the management of patients with malignant pleural mesothelioma (MPM), based on a systematic review of the medical literature.1 This comprehensive guideline consists of 63 recommendations on the diagnosis, staging, chemotherapy treatment, surgical…

  • Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios

    Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios

    Systemic, Targeted, & Immune Therapies

    By D. Ross Camidge, MD, and Mary W. Redman, PhD Posted: August 2018 Updates of the primary analysis of the phase III ALEX trial were presented at the American Society of Clinical Oncology Annual Meeting this year.1,2 ALEX was a first-line trial of crizotinib versus alectinib in advanced ALK-positive NSCLC, and the primary endpoint was…

  • WCLC Plenary Symposia to Include Practice-Changing Research Presentations

    WCLC Plenary Symposia to Include Practice-Changing Research Presentations

    Meeting News

    The conference’s program is stacked with science and education for scientists, clinicians, and advocates alike. By Leah K. Lawrence Posted: August 2018 The IASLC 19th World Conference on Lung Cancer (WCLC), the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, will take place this year from September 23 to 26 in Toronto,…

  • Avrum Spira, MD

    Avrum Spira, MD

    Names & News

    Posted: August 2018 Avrum Spira, MD, has been named global head of the new Lung Cancer Initiative within Johnson & Johnson, which will be based at Boston University’s Medical Campus. This initiative is a 5-year research alliance with Johnson & Johnson Innovation LLC; it aims to develop biomarker-based early-screening tests for lung cancer. Dr. Spira…

View ILCN Archives

Provider Resources

Popular Articles